Get the Stockscreener App
132.57
0.16%
0.21
Novartis Ag Adr stock is traded at $132.57, with a volume of 1.17M.
It is up +0.16% in the last 24 hours and up +0.21% over the past month.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
See More
Previous Close:
$132.36
Open:
$132.37
24h Volume:
1.17M
Relative Volume:
0.71
Market Cap:
$254.37B
Revenue:
$54.45B
Net Income/Loss:
$14.42B
P/E Ratio:
18.08
EPS:
7.333
Net Cash Flow:
$17.15B
1W Performance:
+0.31%
1M Performance:
+0.21%
6M Performance:
+9.77%
1Y Performance:
+34.47%
1-Day Range:
$131.77
$133.01
1-Week Range:
$129.98
$133.84
52-Week Range:
$96.06
$134.24
Novartis Ag Adr Stock (NVS) Company Profile
Name
Novartis Ag Adr
Sector
Industry
Phone
-
Address
-
Compare NVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
132.57 | 253.97B | 54.45B | 14.42B | 17.15B | 7.333 |
|
LLY
Lilly Eli Co
|
1,027.51 | 903.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
211.58 | 505.98B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.32 | 395.86B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
100.30 | 245.75B | 63.90B | 19.05B | 13.05B | 7.5596 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-12-25 | Downgrade | Goldman | Neutral → Sell |
| Aug-08-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-13-25 | Downgrade | UBS | Buy → Neutral |
| Feb-12-25 | Initiated | Morgan Stanley | Underweight |
| Feb-04-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Dec-04-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Sep-11-24 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-05-24 | Downgrade | Goldman | Buy → Neutral |
| Sep-03-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-24 | Downgrade | Deutsche Bank | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-23-24 | Initiated | BMO Capital Markets | Market Perform |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-25-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-26-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-27-23 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-26-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-05-22 | Upgrade | Stifel | Hold → Buy |
| Sep-15-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| May-09-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-10-22 | Resumed | Citigroup | Buy |
| Dec-14-21 | Downgrade | Redburn | Buy → Neutral |
| Dec-06-21 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-03-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Sep-20-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-22-21 | Initiated | Bernstein | Mkt Perform |
| Mar-10-21 | Downgrade | Argus | Buy → Hold |
| Feb-01-21 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Sep-10-20 | Upgrade | UBS | Neutral → Buy |
| Sep-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-15-20 | Upgrade | Citigroup | Neutral → Buy |
| Mar-10-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-25-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-10-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-02-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Underperform → Buy |
| May-29-18 | Downgrade | HSBC Securities | Buy → Hold |
| May-25-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jan-25-18 | Reiterated | Leerink Partners | Outperform |
| Dec-06-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-17 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jul-05-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Mar-09-17 | Initiated | Liberum | Buy |
View All
Novartis Ag Adr Stock (NVS) Latest News
Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report - Insider Monkey
Novartis (NVS) enters $1.7 billion development deal, says report - MSN
Price Over Earnings Overview: Novartis - Sahm
Roche's Oral Breast Cancer Drug Shows 30% Drop In Recurrence In Patients With Early Disease - Benzinga
13 Best ADR Stocks to Invest In - Insider Monkey
Novartis AG (NVS) Gets Upgraded to Overweight from Neutral by JPMorgan - Finviz
Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder - Sahm
Novartis AG (NVS) Announces US FDA Approval of Itvisma - Finviz
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster - Sahm
Baird Financial Group Inc. Cuts Holdings in Novartis AG $NVS - Defense World
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ophthalmic Drugs Market Size to Cross USD 62.74 Billion by 2032, Driven by Advances in Eye Care Treatments and Rising Global Vision Disorders - GlobeNewswire Inc.
Free cash flow per share of Novartis AG Sponsored ADR – GETTEX:NOTA - TradingView
TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029 - Finviz
Why Novartis Stock Topped the Market Today - sharewise.com
Novartis AG Common Stock (NYSE:NVS) Stock Quote - Markets Financial Content
FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults - Sahm
Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN) - The Globe and Mail
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth - Finviz
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts - Sahm
Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110 - Finviz
Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring - Sahm
Net margin % of Novartis AG Sponsored ADR – HAM:NOTA - TradingView
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint - Finviz
Novartis Issues $6 Billion in Debt Securities to Bolster Financial Strategy - The Globe and Mail
Stocks Generating Improved Relative Strength: Novartis ADR - Investor's Business Daily
Novartis' Strong Branded Drug Portfolio Supports Steady Long-Term Growth - Morningstar
Novartis ADR earnings missed by $0.02, revenue topped estimates - Investing.com India
Novartis completes acquisition of Tourmaline Bio - Novartis
'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours - Sahm
Novartis announces expiration of Tourmaline Bio tender offer - Novartis
Stocks Rally on US-China Preliminary Trade Agreement - Barchart.com
Novartis Ag Adr Stock (NVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):